




BACKGROUND NOTE: Each year WHO and UNICEF jointly review reports submitted by Member States regarding national immunization coverage, finalized survey reports as well as data from published and grey literature. Based on these data, with due consideration to potential biases and the views of local experts, WHO and UNICEF attempt to distinguish between situations where available empirical data accurately reflect immunization system performance and those where the data are likely compromised and present a misleading view of coverage.

WHO and UNICEF estimates are country-specific; that is to say, each country's data are reviewed individually, and data are not borrowed from other countries in the absence of data. Estimates are not based on ad hoc adjustments to reported data; in some instances empirical data are available from a single source, usually the nationally reported coverage data. In cases where no data are available for a given country/vaccine/year combination, data are considered from earlier and later years and interpolated to estimate coverage for the missing year(s). In cases where data sources are mixed and show large variation, an attempt is made to identify the most likely estimate with consideration of the possible biases in available data. For methods see:

*Burton et al. 2009. Bull World Health Organ.

*Burton et al. 2012. PLoS One.

*Danovaro-Holliday et al. 2021. Gates Open Res.

DATA SOURCES.

ADMINISTRATIVE coverage: Reported by national authorities and based on aggregated administrative reports from health service providers on the number of vaccinations administered during a given period (numerator data) and reported target population data (denominator data). May be biased by inaccurate numerator and/or denominator data.

OFFICIAL coverage: Estimated coverage reported by national authorities that reflects their assessment of the most likely coverage based on any combination of administrative coverage, survey-based estimates or other data sources or adjustments. Approaches to determine OFFICIAL coverage may differ across countries.

SURVEY coverage: Based on estimated coverage from population-based household surveys among children aged 12-23 or 24-35 months following a review of survey methods and results. Information is based on the combination of vaccination history from documented evidence or caregiver recall. Survey results are considered for the appropriate birth cohort based on data collection period.

ABBREVIATIONS

BCG: percentage of births who received one dose of Bacillus Calmette Guerin vaccine.

DTP1 / DTP3: percentage of surviving infants who received the 1st / 3rd dose, respectively, of diphtheria and tetanus toxoid with pertussis containing vaccine.

Pol3: percentage of surviving infants who received the 3rd dose of polio containing vaccine. May be either oral or inactivated polio vaccine.

IPV1: percentage of surviving infants who received at least one dose of inactivated polio vaccine. In countries utilizing an immunization schedule recommending either (i) a primary series of three doses of oral polio vaccine (OPV) plus at least one dose of IPV where OPV is included in routine immunization and/or campaign or (ii) a sequential schedule of IPV followed by OPV, WHO and UNICEF estimates for IPV1 reflect coverage with at least one routine dose of IPV among infants <1 year of age. For countries utilizing IPV containing vaccine only, i.e., no recommended dose of OPV, WHO and UNICEF estimate for IPV1 corresponds to coverage for the 1st dose of IPV.

Production of IPV coverage estimates, which begins in 2015, results in no change of the estimated coverage levels for the 3rd dose of polio (Pol3). For countries recommending routine immunization with a primary series of three doses of IPV alone, WHO and UNICEF estimated Pol3 coverage is equivalent to estimated coverage with three doses of IPV. For countries with a sequential schedule, estimated Pol3 coverage is based on that for the 3rd dose of polio vaccine regardless of vaccine type.

IPV2: percentage of surviving infants who received a 2nd dose of inactivated polio vaccine. IPV2 coverage estimates produced for OPV using countries.

MCV1: percentage of surviving infants who received the 1st dose of measles containing vaccine. In countries where the national schedule recommends the 1st dose of MCV at 12 months or later based on the epidemiology of disease in the country, coverage estimates reflect the percentage of children who received the 1st dose of MCV as recommended.

MCV2: percentage of children who received the 2nd dose of measles containing vaccine according to the nationally recommended schedule.

RCV1: percentage of surviving infants who received the 1st dose of rubella containing vaccine. Coverage estimates are based on WHO and UNICEF estimates of coverage for the dose of measles containing vaccine that corresponds to the first measles-rubella combination vaccine. Nationally reported coverage of RCV is not taken into consideration nor are the data represented in the accompanying graph and data table.

HepBB: percentage of births which received a dose of hepatitis B vaccine within 24 hours of delivery. Estimates of hepatitis B birth dose coverage are produced only for countries with a universal birth dose policy. Estimates are not produced for countries that recommend a birth dose to infants born to HepB virus-infected mothers only or where there is insufficient information to determine whether vaccination is within 24 hours of birth.

HepB3: percentage of surviving infants who received the 3rd dose of hepatitis B containing vaccine following the birth dose.

Hib3: percentage of surviving infants who received the 3rd dose of Haemophilus influenzae type b containing vaccine.

RotaC: percentage of surviving infants who received the final recommended dose of rotavirus vaccine, which can be either the 2nd or the 3rd dose depending on the vaccine.

PcV3: percentage of surviving infants who received the 3rd dose of pneumococcal conjugate vaccine. In countries where the national schedule recommends two doses during infancy and a booster dose at 12 months or later based on the epidemiology of disease in the country, coverage estimates may reflect the percentage of surviving infants who received two doses of PcV prior to the 1st birthday.


YFV: percentage of surviving infants who received one dose of yellow fever vaccine in countries where YFV is part of the national immunization schedule for children or is recommended in at risk areas; coverage estimates are annualized for the entire cohort of surviving infants.

MengA: percentage of children who received one dose of meningococcal A conjugate vaccine. MengA coverage estimates produced for countries in the meningitis belt of sub-Saharan Africa.

Disclaimer: All reasonable precautions have been taken by the World Health Organization and United Nations Children's Fund to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization or United Nations Children's Fund be liable for damages arising from its use.

Papua New Guinea - BCG

PNG - BCG



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	91	93	84	67	72	62	52	45	52	42	48	43
Estimate GoC	●	●	●	●	●	●	●	●	●	●	●	●
Official	84	88	81	65	72	62	52	45	52	42	48	43
Administrative	80	86	77	61	68	57	47	45	52	42	48	43
Survey	NA	NA	NA	NA	69	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.


- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2023: Estimate informed by reported data. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate challenged by: D-
- 2022: Estimate informed by reported data. Reported data reflect 94 percent of expected district level reports. Programme reports three months vaccine stockout at national and subnational levels. Estimate challenged by: D-
- 2021: Estimate informed by reported data. Estimate challenged by: D-
- 2020: Estimate informed by reported data. Estimate challenged by: D-
- 2019: Estimate informed by reported data. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. GoC=Assigned by working group. Consistency with other antigens.
- 2018: Estimate informed by reported data. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Estimate informed by reported data. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- 2016: Estimate informed by reported data supported by survey. Survey evidence of 69 percent based on 1 survey(s). Reported data reflects three quarters of expected district-level reports. Programme reports 3.5 months stockout at national level. GoC=Assigned by working group. See comment in 2018.
- 2015: Reported data calibrated to 2005 and 2016 levels. Programme reports a three months vaccine stockout at national level. GoC=Assigned by working group. See comment in 2018.
- 2014: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. Programme reports two months stockout at national level. GoC=Assigned by working group. See comment in 2018.
- 2013: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2012: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - HepBB



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	35	37	31	32	35	33	25	21	24	22	24	26
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	35	37	31	32	35	33	25	21	24	22	24	26
Administrative	30	34	27	28	31	28	20	21	24	22	24	26
Survey	NA	NA	NA	NA	58	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2023: Estimate informed by reported data. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate exceptionally based on reported data. Estimate challenged by: D-
- 2022: Estimate informed by reported data. Reported data reflect 94 percent of expected district level reports. GoC=Assigned by working group. Consistency with GoC for other vaccine-doses.
- 2021: Estimate informed by reported data. GoC=Assigned by working group. Consistency with GoC for other vaccine-doses.
- 2020: Estimate informed by reported data. GoC=Assigned by working group. Consistency with GoC for other vaccine-doses.
- 2019: Estimate informed by reported data. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. GoC=Assigned by working group. Consistency with other antigens.
- 2018: Estimate informed by reported data. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Estimate informed by reported data. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- 2016: Estimate informed by reported data. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results ignored due to insufficient information regarding whether HepB doses were received within 24 hours of birth. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- 2015: Estimate informed by reported data. GoC=Assigned by working group. See comment in 2018.
- 2014: Estimate informed by reported data. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.
- 2013: Estimate informed by reported data. Programme reports two months stockout at national level. GoC=Assigned by working group. See comment in 2018.
- 2012: Estimate informed by reported data. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - DTP1

PNG - DTP1



Description:

- 2023: Reported data calibrated to 2019 levels. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate challenged by: D-R-
- 2022: Reported data calibrated to 2019 levels. Reported data reflect 94 percent of expected district level reports. Estimate of 47 percent changed from previous revision value of 45 percent. Estimate challenged by: D-R-
- 2021: Reported data calibrated to 2019 levels. Estimate of 41 percent changed from previous revision value of 39 percent. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2019 levels. Estimate of 50 percent changed from previous revision value of 48 percent. Estimate challenged by: D-R-
- 2019: Estimate of 44 percent assigned by working group. Based on previous year estimate. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-
- 2018: Estimate of 44 percent assigned by working group. Based on calibration in relationship with 2016 survey. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Reported data calibrated to 2016 and 2018 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- 2016: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 64 percent based on 1 survey(s). Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- 2015: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2014: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.
- 2013: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2012: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	71	71	68	62	64	46	44	44	50	41	47	45
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	85	88	87	83	87	69	67	55	61	52	58	56
Administrative	82	94	83	79	83	64	62	55	61	52	58	56
Survey	NA	NA	NA	NA	64	NA	NA	NA	NA	NA	NA	NA


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Papua New Guinea - DTP3

PNG - DTP3



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	57	60	52	49	46	36	35	35	40	32	37	35
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	63	68	62	62	61	51	50	40	45	37	42	40
Administrative	59	64	58	58	57	46	45	40	45	37	42	40
Survey	NA	NA	NA	NA	42	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.


- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2023: Reported data calibrated to 2019 levels. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate challenged by: D-R-
- 2022: Reported data calibrated to 2019 levels. Reported data reflect 94 percent of expected district level reports. Estimate of 37 percent changed from previous revision value of 36 percent. Estimate challenged by: D-R-
- 2021: Reported data calibrated to 2019 levels. Estimate of 32 percent changed from previous revision value of 31 percent. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2019 levels. Estimate of 40 percent changed from previous revision value of 39 percent. Estimate challenged by: D-R-
- 2019: Estimate of 35 percent assigned by working group. Based on previous year estimate. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-
- 2018: Estimate of 35 percent assigned by working group. Based on calibration in relationship with 2016 survey. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Reported data calibrated to 2016 and 2018 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- 2016: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 46 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 42 percent modified for recall bias to 46 percent based on 1st dose card or history coverage of 64 percent, 1st dose card only coverage of 50 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- 2015: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2014: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.
- 2013: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2012: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - HepB3



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	57	59	52	49	46	36	35	35	40	32	37	35
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	63	68	62	62	61	51	50	40	45	37	42	40
Administrative	59	64	58	58	57	46	45	40	45	37	42	40
Survey	NA	NA	NA	NA	42	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2023: Reported data calibrated to 2019 levels. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate challenged by: D-R-
- 2022: Reported data calibrated to 2019 levels. Reported data reflect 94 percent of expected district level reports. Estimate of 37 percent changed from previous revision value of 36 percent. Estimate challenged by: D-R-
- 2021: Reported data calibrated to 2019 levels. Estimate of 32 percent changed from previous revision value of 31 percent. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2019 levels. Estimate of 40 percent changed from previous revision value of 39 percent. Estimate challenged by: D-R-
- 2019: Estimate of 35 percent assigned by working group. Based on previous year estimate. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-
- 2018: Estimate of 35 percent assigned by working group. Based on calibration in relationship with 2016 survey. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Reported data calibrated to 2016 and 2018 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- 2016: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 46 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 42 percent modified for recall bias to 46 percent based on 1st dose card or history coverage of 64 percent, 1st dose card only coverage of 50 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- 2015: Reported data calibrated to 2012 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2014: Reported data calibrated to 2012 and 2016 levels. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.
- 2013: Reported data calibrated to 2012 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2012: Estimate of 57 percent assigned by working group. Estimate informed by estimated DTP3 coverage. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - Hib3

PNG - Hib3



Description:

- 2023: Reported data calibrated to 2019 levels. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate challenged by: D-R-
- 2022: Reported data calibrated to 2019 levels. Reported data reflect 94 percent of expected district level reports. Estimate of 37 percent changed from previous revision value of 36 percent. Estimate challenged by: D-R-
- 2021: Reported data calibrated to 2019 levels. Estimate of 32 percent changed from previous revision value of 31 percent. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2019 levels. Estimate of 40 percent changed from previous revision value of 39 percent. Estimate challenged by: D-R-
- 2019: Estimate of 35 percent assigned by working group. Based on previous year estimate. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: D-R-
- 2018: Estimate of 35 percent assigned by working group. Based on calibration in relationship with 2016 survey. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Reported data calibrated to 2016 and 2018 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- 2016: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 46 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 42 percent modified for recall bias to 46 percent based on 1st dose card or history coverage of 64 percent, 1st dose card only coverage of 50 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- 2015: Reported data calibrated to 2012 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2014: Reported data calibrated to 2012 and 2016 levels. Target population increase of 13 percent compared to 2013. GoC=Assigned by working group. See comment in 2018.
- 2013: Reported data calibrated to 2012 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2012: Estimate of 57 percent assigned by working group. Estimate informed by estimated DTP3 coverage. GoC=Assigned by working group. See comment in 2018.


	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	57	59	52	49	46	36	35	35	40	32	37	35
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	63	68	62	62	61	51	50	40	45	37	42	40
Administrative	59	64	58	58	57	46	45	40	45	37	42	40
Survey	NA	NA	NA	NA	42	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Papua New Guinea - RotaC



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Estimate GoC	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Official	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Administrative	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Papua New Guinea - PcV3

PNG - PcV3



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	NA	NA	NA	20	35	35	35	35	41	34	38	29
Estimate GoC	NA	NA	NA	•	•	•	•	•	•	•	•	•
Official	NA	NA	NA	20	20	44	43	38	44	37	41	32
Administrative	NA	NA	NA	16	16	39	38	38	44	37	41	32
Survey	NA	NA	NA	NA	35	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2023: Reported data calibrated to 2019 levels. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Programme reports a two-month vaccine stockout at national and subnational levels. Estimate challenged by: D-R-
- 2022: Reported data calibrated to 2019 levels. Reported data reflect 94 percent of expected district level reports. Programme reports three months vaccine stockout at national and subnational levels. Estimate of 38 percent changed from previous revision value of 35 percent. Estimate challenged by: D-R-
- 2021: Reported data calibrated to 2019 levels. Estimate of 34 percent changed from previous revision value of 32 percent. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2019 levels. Estimate of 41 percent changed from previous revision value of 39 percent. Estimate challenged by: D-R-
- 2019: Estimate of 35 percent assigned by working group. Based on estimate for DTP3 for consistency. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: R-
- 2018: Estimate of 35 percent assigned by working group. Estimate is based on estimated DTP3. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. Estimate based on reported data during period of introduction. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Estimate of 36 percent assigned by working group. Estimate is based on estimated DTP3. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Estimate based on reported data during period of introduction. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- 2016: Estimate is based on reported data. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results ignored during period of introduction. Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 35 percent modified for recall bias to 39 percent based on 1st dose card or history coverage of 58 percent, 1st dose card only coverage of 46 percent and 3rd dose card only coverage of 31 percent. Reported data reflects three quarters of expected district-level reports. Estimate based on reported data during period of introduction. GoC=Assigned by working group. See comment in 2018.
- 2015: Estimate informed by reported data. Pneumococcal conjugate vaccine introduced in 2013. Reporting began in 2015. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - Pol3

PNG - Pol3



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	65	62	43	51	48	35	42	42	43	34	38	46
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	70	69	53	63	62	49	56	44	45	36	40	48
Administrative	69	66	49	59	58	44	51	44	45	36	40	48
Survey	NA	NA	NA	NA	42	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:


- 2023: Reported data calibrated to 2019 levels. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Reported coverage likely includes campaign doses. Programme reports a five-month vaccine stockout at national and subnational levels. Estimate challenged by: D-R-
- 2022: Reported data calibrated to 2019 levels. Reported data reflect 94 percent of expected district level reports. Estimate of 38 percent changed from previous revision value of 36 percent. Estimate challenged by: D-R-
- 2021: Reported data calibrated to 2019 levels. Estimate of 34 percent changed from previous revision value of 32 percent. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2019 levels. Programme reports half month vaccine stockout at national and district level. Estimate of 43 percent changed from previous revision value of 41 percent. Estimate challenged by: D-R-
- 2019: Estimate of 42 percent assigned by working group. Based on previous year estimate. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: R-
- 2018: Estimate of 42 percent assigned by working group. Based on calibration in relationship with 2016 survey. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Reported data calibrated to 2016 and 2018 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.
- 2016: Survey evidence does not support reported data. Estimate based on survey results. Survey evidence of 48 percent based on 1 survey(s). Papua New Guinea Demographic and Health Survey 2016-2018 card or history results of 42 percent modified for recall bias to 48 percent based on 1st dose card or history coverage of 69 percent, 1st dose card only coverage of 52 percent and 3rd dose card only coverage of 36 percent. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- 2015: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2014: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. Programme reports two months stockout at national level. GoC=Assigned by working group. See comment in 2018.
- 2013: Reported data calibrated to 2005 and 2016 levels. Programme reports three months stockout at national level. GoC=Assigned by working group. See comment in 2018.
- 2012: Reported data calibrated to 2005 and 2016 levels. Rise in coverage is attributable to

Papua New Guinea - Pol3

recovery from vaccine shortage. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - IPV1

PNG - IPV1



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	NA	NA	NA	NA	14	32	35	35	40	32	46	42
Estimate GoC	NA	NA	NA	NA	•	•	•	•	•	•	•	•
Official	NA	NA	NA	NA	14	32	35	34	50	42	57	53
Administrative	NA	NA	NA	NA	10	27	30	34	50	42	57	53
Survey	NA	NA	NA	NA	39	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative's Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV).

2023: Estimate is informed by the relative relationship between reported administrative coverage and estimated coverage for DTP1 applied to reported administrative coverage for IPV1. During 2022, the reported number of doses administered for IPV1, recommended at 3 months of age, was more similar to that for DTP1 than for DTP3. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate challenged by: D-R-

2022: Estimate is informed by the relative relationship between reported administrative coverage and estimated coverage for DTP1 applied to reported administrative coverage for IPV1. During 2022, the reported number of doses administered for IPV1, recommended at 3 months of age, was more similar to that for DTP1 than for DTP3. Reported data reflect 94 percent of expected district level reports. Estimate of 46 percent changed from previous revision value of 44 percent. Estimate challenged by: D-R-

2021: Estimate is based on DTP3 estimated coverage. Estimate reflects decline in reported coverage from 2020. Estimate of 32 percent changed from previous revision value of 31 percent. Estimate challenged by: D-R-

2020: Based on estimate for DTP3 coverage for consistency but it may underestimate IPV1 coverage given that more IPV than DTP3 doses reported. Estimate of 40 percent changed from previous revision value of 39 percent. Estimate challenged by: D-R-

2019: Estimate of 35 percent assigned by working group. Based on estimate for DTP3 coverage. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Actual IPV1 coverage is likely lower than that estimated based on reported doses administered vis-a-vis the third dose of DTP. GoC=Assigned by working group. Consistency with other antigens recommended at the same age.

2018: Based on estimated DTP3 coverage. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. Estimate based on reported data during period of introduction. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.


2017: Estimate informed by reported data. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Estimate based on reported data during period of introduction. Consistent decline in reported coverage for almost all vaccines. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - IPV1

2016: Estimate informed by reported data. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results ignored during period of introduction. Reported data reflects three quarters of expected district-level reports. Inactivated polio vaccine in 2015, reporting starts in 2016. Unclear whether doses given as part of an intensification of routine vaccination are included in the reported coverage. Programme reports two months stockout of IPV at national level. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - IPV2

PNG - IPV2



Description:

Estimates for a second dose of inactivated polio vaccine (IPV) begin in 2021 following a Strategic Advisory Group of Experts on Immunization (SAGE) recommendation in October 2020 that a second IPV dose increases protection against all polioviruses, including protection against paralysis caused by vaccine derived polio virus (type 2) (VDPV2). The addition of IPV2 is the next step towards complete OPV withdrawal. IPV2 coverage estimates produced for OPV using countries.

2023: IPV2 not yet included in PNG National Health Information system. 10 percent of health facilities reported data for 2023. Therefore our estimate is based on previous year estimate. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage.. Estimate challenged by: D-R-

2022: Estimate is based on relative relationship between estimated and reported coverage for IPV1 applied to reported coverage for IPV2. Reported data reflect 94 percent of expected district level reports.. Estimate challenged by: D-R-

2021: Estimate informed by reported data. Second dose of inactivated polio vaccine introduced during 2021. GoC=R+ D+

	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	NA	NA	NA	NA	NA	NA	NA	NA	NA	1	36	36
Estimate GoC	NA	NA	NA	NA	NA	NA	NA	NA	NA	••	•	•
Official	NA	NA	NA	NA	NA	NA	NA	NA	NA	1	46	0
Administrative	NA	NA	NA	NA	NA	NA	NA	NA	NA	1	46	0
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA


The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Papua New Guinea - MCV1

PNG - MCV1



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	71	72	65	57	46	41	37	37	44	35	41	52
Estimate GoC	•	•	•	•	•	•	•	•	••	••	•	•
Official	67	70	65	60	51	43	42	33	44	35	41	52
Administrative	64	65	61	56	47	38	37	33	44	35	41	52
Survey	NA	NA	NA	NA	59	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2023: Estimate informed by reported data. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Reported coverage likely includes campaign doses. Programme reports a one month vaccine stockout at national level. Estimate challenged by: D-
- 2022: Estimate informed by reported data. Reported data reflect 94 percent of expected district level reports. Estimate of 41 percent changed from previous revision value of 44 percent. Estimate challenged by: D-
- 2021: Estimate informed by reported data. Estimate of 35 percent changed from previous revision value of 38 percent. GoC=R+ D+
- 2020: Estimate informed by reported data. Estimate of 44 percent changed from previous revision value of 47 percent. GoC=R+ D+
- 2019: Based on previous year estimate. Observed decline in reported coverage for several antigens appears to reflect unexplained seven percent increase in target population. Year to year population growth was previously around three percent. Estimate challenged by: R-
- 2018: Based on calibration in relationship with 2016 survey. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent.. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Reported data calibrated to 2016 and 2018 levels. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. Estimate of 41 percent changed from previous revision value of 38 percent. GoC=Assigned by working group. See comment in 2018.
- 2016: Estimate of 46 percent assigned by working group. Estimate is based on estimated DTP3 level. Reported administrative data suggests MCV1 coverage is lower than that for DTP3. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results may included doses delivered through campaign. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- 2015: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2014: Reported data calibrated to 2005 and 2016 levels. Target population increase of 13 percent compared to 2013. Programme reports two months stockout at national level. GoC=Assigned by working group. See comment in 2018.
- 2013: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.
- 2012: Reported data calibrated to 2005 and 2016 levels. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - RCV1

PNG - RCV1



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	NA	NA	NA	57	46	41	37	37	44	35	41	52
Estimate GoC	NA	NA	NA	●	●	●	●	●	●●	●●	●	●
Official	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Administrative	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Survey	NA	NA	NA	NA	59	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

For this revision, coverage estimates for the first dose of rubella containing vaccine are based on WHO and UNICEF estimates of coverage of measles containing vaccine. Nationally reported coverage of rubella containing vaccine is not taken into consideration nor are they represented in the the accompanying graph and data table.

- 2023: Estimate based on estimated MCV1. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate challenged by: D-
- 2022: Estimate based on estimated MCV1. Reported data reflect 94 percent of expected district level reports. Estimate of 41 percent changed from previous revision value of 44 percent. Estimate challenged by: D-
- 2021: Estimate based on estimated MCV1. Estimate of 35 percent changed from previous revision value of 38 percent. GoC=R+ D+
- 2020: Estimate based on estimated MCV1. Estimate of 44 percent changed from previous revision value of 47 percent. GoC=R+ D+
- 2019: Estimate is based on estimated MCV1 coverage level. Estimate challenged by: R-
- 2018: Estimate based on estimated MCV1. Programme reports do not include private sector providers. Programme notes administrative reporting completeness is 78 percent. GoC=Assigned by working group. Fluctuation in reported coverage across the time series suggests challenges in routine monitoring system.
- 2017: Estimate based on estimated MCV1. Programme reports that persistent challenges contributed to the declines in coverage for 2017. Consistent decline in reported coverage for almost all vaccines. Estimate of 41 percent changed from previous revision value of 38 percent. GoC=Assigned by working group. See comment in 2018.
- 2016: Estimate based on estimated MCV1. Papua New Guinea Demographic and Health Survey 2016-2018 results ignored by working group. Survey results may included doses delivered through campaign. Reported data reflects three quarters of expected district-level reports. GoC=Assigned by working group. See comment in 2018.
- 2015: Estimate based on estimated MCV1. GoC=Assigned by working group. See comment in 2018.

Papua New Guinea - MCV2



	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
Estimate	NA	NA	NA	NA	NA	NA	NA	20	27	20	25	41
Estimate GoC	NA	NA	NA	NA	NA	NA	NA	●	●	●	●	●
Official	NA	NA	NA	NA	NA	NA	NA	20	27	20	25	48
Administrative	NA	NA	NA	NA	NA	NA	NA	20	27	20	25	48
Survey	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2022 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

Coverage estimates for the second dose of measles containing vaccine are for children by the nationally recommended age.

- 2023: Reported coverage likely includes campaign doses. Programme reports a one month vaccine stockout at national level. Estimate is based on the relationship between reported MCV1 and MCV2 doses applied to the estimated MCV1 coverage. Reported data excluded due to sudden change in coverage from 25 level to 48 percent. No nationally representative household survey for the most recent 5 annual birth cohorts. WHO and UNICEF recommend a high quality survey to verify reported levels of coverage. Estimate challenged by: D-R-
- 2022: Estimate informed by reported data. Reported data reflect 94 percent of expected district level reports. GoC=Assigned by working group. Consistency with other antigens recommended at the same age.
- 2021: Estimate informed by reported data. GoC=Assigned by working group. Consistency with other antigens recommended at the same age.
- 2020: Estimate informed by reported data. GoC=Assigned by working group. Consistency with other antigens recommended at the same age.
- 2019: Estimate informed by reported data. Estimate is based on reported data on an exceptional basis relative to other antigens. GoC=Assigned by working group. Consistency with other antigens recommended at the same age.

Papua New Guinea - survey details

NOTE: A survey to measure vaccination coverage for infants (i.e., children aged 0-11 months) will sample children aged 12-23 months at the time of survey to capture the youngest annual cohort of children who should have completed the vaccination schedule. Because WUENIC are for infant vaccinations, survey data in this report are presented to reflect the birth year of the youngest survey cohort. For example, results for a survey conducted during December 2020 among children aged 12-23 months at the time of the survey reflect the immunization experience of children born in 2019. Depending on the timing of survey field work, results may reflect the immunization experience of children born and vaccinated 1 or 2 years prior to the survey field work.

2016 Papua New Guinea Demographic and Health Survey 2016-2018

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Cards seen
BCG	C or H <12 months	67.1	12-23 m	1763	61
BCG	Card	52.9	12-23 m	1069	61
BCG	Card or History	69.4	12-23 m	1763	61
BCG	History	16.5	12-23 m	695	61
DTP1	C or H <12 months	60.9	12-23 m	1763	61
DTP1	Card	50	12-23 m	1069	61
DTP1	Card or History	63.9	12-23 m	1763	61
DTP1	History	13.9	12-23 m	695	61
DTP3	C or H <12 months	35	12-23 m	1763	61
DTP3	Card	35.9	12-23 m	1069	61
DTP3	Card or History	41.7	12-23 m	1763	61
DTP3	History	5.8	12-23 m	695	61
HepB1	C or H <12 months	60.9	12-23 m	1763	61
HepB1	Card	50	12-23 m	1069	61
HepB1	Card or History	63.9	12-23 m	1763	61
HepB1	History	13.9	12-23 m	695	61
HepB3	C or H <12 months	35	12-23 m	1763	61
HepB3	Card	35.9	12-23 m	1069	61
HepB3	Card or History	41.7	12-23 m	1763	61
HepB3	History	5.8	12-23 m	695	61
HepBB	C or H <12 months	55.5	12-23 m	1763	61
HepBB	Card	43.3	12-23 m	1069	61
HepBB	Card or History	57.5	12-23 m	1763	61
HepBB	History	14.2	12-23 m	695	61

Hib1	C or H <12 months	60.9	12-23 m	1763	61
Hib1	Card	50	12-23 m	1069	61
Hib1	Card or History	63.9	12-23 m	1763	61
Hib1	History	13.9	12-23 m	695	61
Hib3	C or H <12 months	35	12-23 m	1763	61
Hib3	Card	35.9	12-23 m	1069	61
Hib3	Card or History	41.7	12-23 m	1763	61
Hib3	History	5.8	12-23 m	695	61
IPV1	C or H <12 months	33.4	12-23 m	1763	61
IPV1	Card	26.4	12-23 m	1069	61
IPV1	Card or History	39.1	12-23 m	1763	61
IPV1	History	12.7	12-23 m	695	61
MCV1	C or H <12 months	50.1	12-23 m	1763	61
MCV1	Card	45.5	12-23 m	1069	61
MCV1	Card or History	58.7	12-23 m	1763	61
MCV1	History	13.2	12-23 m	695	61
PcV1	C or H <12 months	54.2	12-23 m	1763	61
PcV1	Card	46.3	12-23 m	1069	61
PcV1	Card or History	58.3	12-23 m	1763	61
PcV1	History	12	12-23 m	695	61
PcV3	C or H <12 months	28.7	12-23 m	1763	61
PcV3	Card	31.3	12-23 m	1069	61
PcV3	Card or History	35.4	12-23 m	1763	61
PcV3	History	4	12-23 m	695	61
Pol1	C or H <12 months	66	12-23 m	1763	61
Pol1	Card	52.1	12-23 m	1069	61
Pol1	Card or History	69	12-23 m	1763	61
Pol1	History	16.9	12-23 m	695	61
Pol3	C or H <12 months	35.9	12-23 m	1763	61
Pol3	Card	36.2	12-23 m	1069	61
Pol3	Card or History	42.2	12-23 m	1763	61
Pol3	History	6	12-23 m	695	61

2005 Papua New Guinea Demographic and Health Survey 2006

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Cards seen
BCG	Card	66.7	12-23 m	883	70
BCG	Card or History	89.6	12-23 m	1254	70
DTP1	Card	66.5	12-23 m	883	70

Papua New Guinea - survey details

DTP1	Card or History	87.9	12-23 m	1254	70
DTP3	Card	53.7	12-23 m	883	70
DTP3	Card or History	66.8	12-23 m	1254	70
HepB1	Card	64.8	12-23 m	883	70
HepB1	Card or History	86.4	12-23 m	1254	70
HepB3	Card	53.3	12-23 m	883	70
HepB3	Card or History	64.6	12-23 m	1254	70
MCV1	Card	61.6	12-23 m	883	70
MCV1	Card or History	81.6	12-23 m	1254	70
Pol1	Card	64.9	12-23 m	883	70
Pol1	Card or History	87.4	12-23 m	1254	70
Pol3	Card	54.6	12-23 m	883	70
Pol3	Card or History	68.3	12-23 m	1254	70

2004 National Immunization Coverage Survey 2005-2006, Papua New Guinea

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Cards seen
BCG	Card	81.3	12-23 m	783	93
BCG	Card or History	90.3	12-23 m	783	93
BCG	History	9	12-23 m	783	93

DTP1	Card	81.8	12-23 m	776	93
DTP1	Card or History	87.5	12-23 m	776	93
DTP1	History	5.7	12-23 m	776	93
DTP3	Card	66.8	12-23 m	783	93
DTP3	Card or History	71	12-23 m	783	93
DTP3	History	4.2	12-23 m	783	93
HepB1	Card	82.1	12-23 m	774	93
HepB1	Card or History	88.1	12-23 m	774	93
HepB1	History	6	12-23 m	774	93
HepB3	Card	68.7	12-23 m	774	93
HepB3	Card or History	73.1	12-23 m	774	93
HepB3	History	4.4	12-23 m	774	93
MCV1	Card	71.9	12-23 m	776	93
MCV1	Card or History	77.9	12-23 m	776	93
MCV1	History	6	12-23 m	776	93
Pol1	Card	79.3	12-23 m	774	93
Pol1	Card or History	84.6	12-23 m	774	93
Pol1	History	5.3	12-23 m	774	93
Pol3	Card	64	12-23 m	776	93
Pol3	Card or History	68.7	12-23 m	776	93
Pol3	History	4.7	12-23 m	776	93

Papua New Guinea - survey details

Further information and estimates for previous years are available at:

<https://data.unicef.org/topic/child-health/immunization/>

<https://immunizationdata.who.int/listing.html>